These treatments help patients recover faster
Each 3ml vial contains approximately 5mg BPC-157 and 10mg TB-500, pre-mixed at an optimal ratio by a licensed compounding pharmacy

Proposed use: Ulcerative colitis Proposed forms: Oral capsules, nasal spray, injections, transdermal cream, rectal suppository Proposed use: Wound healing Proposed forms: Subcutaneous or intramuscular injection Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests Proposed use: Wound healing and inflammatory condition Proposed forms: Cream and gel Proposed use: Obesity and osteoporosis Proposed forms: Subcutaneous injection Proposed use: Cerebral ischemia (shortage of blood flow and oxygen to the brain), migraine and trigeminal neuralgia (chronic pain condition in the face) Proposed form: Intranasal spray, subcutaneous injection Click Here To Sign Up For Our Health Newsletter Proposed use: Opioid withdrawal, chronic insomnia, narcolepsy Proposed form: Subcutaneous injection Proposed use: Insomnia Proposed form: Subcutaneous injection Performance medicine and peptide expert Dr
View the benefits and research on TB500 peptide here
Concentration accuracy is harder than it looks The 0.9% benzyl alcohol target is a narrow window with consequences on both sides: Too little benzyl alcohol (below ~0.5%) and the bacteriostatic effect weakens significantly, allowing bacterial growth in the multi-dose vial during the 28-day use window Too much benzyl alcohol (above ~2%) and tissue toxicity becomes a concern published research has documented injection site irritation, tissue damage, and in extreme concentrations, systemic toxicity from benzyl alcohol exposure For a 30 mL batch, the target benzyl alcohol volume is 0.27 mL roughly five drops from a standard dropper
FDA warnings back in the golden age of peptides: including on compounding marketing